Director Michelle Patricia Pernice filed an initial statement of beneficial ownership with the SEC on November 12, 2026, reporting 27,868 shares of common stock in InMed Pharmaceuticals Inc. (trading as NASDAQ:MTRI) received through a merger effective November 6, 2026.

Key Highlights

  • Reporting person: Michelle Patricia Pernice, listed as a Director of the issuer.
  • Shares reported: 27,868 shares of common stock held directly, received in the Merger in exchange for shares of Pre-Merger Mentari Therapeutics, Inc. common stock.
  • Exchange ratio: Each share of Pre-Merger Mentari's restricted common stock was exchanged for 0.20065 restricted shares of the issuer's common stock, according to the filing.
  • Vesting restriction: Of the 27,868 shares, 19,740 remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to continued service.
  • Event date: The date of the event requiring the statement was November 6, 2026, the effective time of the merger.
  • No derivative securities: The filing reports no derivative securities beneficially owned in Table II.

Pernice's Initial Ownership Stake Following the InMed-Mentari Merger

According to the filing, the event triggering this initial beneficial ownership report was a two-step merger effective November 6, 2026. The filing states that Indigo Merger Sub Corp., a wholly owned subsidiary of InMed Pharmaceuticals Inc. (which the filing describes as "formerly known as InMed Pharmaceuticals Inc." and now operating under the name Mentari Therapeutics, Inc., a Nevada corporation), merged with and into Pre-Merger Mentari Therapeutics, Inc., a Delaware corporation, in a First Merger. Immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the issuer, with that entity surviving under the name Mentari Therapeutics Operating Company LLC, completing the Second Merger.

As a result of the Merger, Pernice received 27,868 shares of the issuer's common stock in exchange for her pre-Merger Mentari shares, at the stated exchange ratio of 0.20065 restricted shares per pre-Merger share. The filing notes that 19,740 of those shares remain subject to forfeiture restrictions, vesting in equal monthly installments through August 13, 2029, contingent on the reporting person's continued service to the issuer on each vesting date. The remaining shares are not described as subject to such restrictions. All shares are reported as held directly.

The form was signed by Jerad G. Seurer as attorney-in-fact for Michelle Pernice, pursuant to a Power of Attorney listed as Exhibit 24. No derivative securities were reported in Table II of the filing.

What Was Disclosed

This Form 3 discloses Director Michelle Patricia Pernice's initial beneficial ownership of 27,868 directly held shares of InMed Pharmaceuticals Inc. (NASDAQ:MTRI) common stock, acquired through a merger effective November 6, 2026, with 19,740 shares remaining subject to vesting restrictions through August 13, 2029.